# LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Study · id `cardio:ct-nct04060914` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04060914](<https://clinicaltrials.gov/study/NCT04060914>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04060914

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 225 participants.

## Technical summary

Registry record NCT04060914. Randomized; no masking; primary purpose treatment. Start 2019-08-30 (anticipated); primary completion 2020-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 225 participants (planned count; ClinicalTrials.gov record NCT04060914, source copy `cardio:ctgov-nct04060914-2019-08-19`, retrieved 2026-10-26)
- Planned start: 2019-08-30 (anticipated) (ClinicalTrials.gov record NCT04060914, source copy `cardio:ctgov-nct04060914-2019-08-19`, retrieved 2026-10-26)
- Primary completion: 2020-12-30 (anticipated) (ClinicalTrials.gov record NCT04060914, source copy `cardio:ctgov-nct04060914-2019-08-19`, retrieved 2026-10-26)
- Completion: 2021-12-30 (anticipated) (ClinicalTrials.gov record NCT04060914, source copy `cardio:ctgov-nct04060914-2019-08-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04060914, source copy `cardio:ctgov-nct04060914-2019-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04060914-2019-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
- Acronym: LOTIC
- Condition: Antiplatelet Therapy
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Ticagrelor 90mg
- Intervention (Drug): Ticagrelor 90mg/60mg
- Intervention (Drug): Clopidogrel 75mg
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 2665ab8801bab3e52e713027d07add3cc211fe1882be7df27523bcdccdf64e33
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
